Shimaa Badawy

Shimaa Badawy


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2020 in Viruses
Verified
Journal Article
Open access
PDF file
SBShimaa Badawy
Shimaa Badawy
MPMaria Pajunen
Maria Pajunen
JHJohanna Haiko
Johanna Haiko
ZBZakaria Baka
Zakaria Baka
MAMohamed I. Abou-Dobara
Mohamed I. Abou-Dobara
Mikael SkurnikMikael Skurnik
Mikael Skurnik
Acinetobacter baumannii is an opportunistic pathogen that presents a serious clinical challenge due to its increasing resistance to all available antibiotics. Phage therapy has been introduced recently to treat antibiotic-incurable A. baumannii infections. In search for new A. baumannii specific bacteriophages, 20 clinical A. baumannii strains were used in two pools in an attempt to enrich phages from sewage. The enrichment resulted in induction of resident prophage(s) and three temperate bacteriophages, named vB_AbaS_fEg-Aba01, vB_AbaS_fLi-Aba02 and vB_AbaS_fLi-Aba03, all able to infect only one strain (#6597) of the 20 clinical strains, were isolated. Morphological characteristics obtained by transmission electron microscopy together with the genomic information revealed that the phages belong to the family Siphoviridae. The ca. 35 kb genomic sequences of the phages were >99% identical to each other. The linear ds DNA genomes of the phages contained 10 nt cohesive end termini, 52–54 predicted genes, an attP site and one tRNA gene each. A database search revealed an >99% identical prophage in the genome of A. baumannii strain AbPK1 (acc. no. CP024576.1). Over 99% identical prophages were also identified from two of the original 20 clinical strains (#5707 and #5920) and both were shown to be spontaneously inducible, thus very likely being the origins of the isolated phages. The phage vB_AbaS_fEg-Aba01 was also able to lysogenize the susceptible strain #6597 demonstrating that it was fully functional. The phages showed a very narrow host range infecting only two A. baumannii strains. In conclusion, we have isolated and characterized three novel temperate Siphoviridae phages that infect A. baumannii.

10 April 2022 in Archives of Virology
Verified
Journal Article
Open access
PDF file
SBShimaa Badawy
Shimaa Badawy
ZBZakaria Baka
Zakaria Baka
MAMohamed I. Abou-Dobara
Mohamed I. Abou-Dobara
AEAhmed K. A. El-Sayed
Ahmed K. A. El-Sayed
Mikael SkurnikMikael Skurnik
Mikael Skurnik
Characterization of bacteriophages facilitates better understanding of their biology, host specificity, genomic diversity, and adaptation to their bacterial hosts. This, in turn, is important for the exploitation of phages for therapeutic purposes, as the use of uncharacterized phages may lead to treatment failure. The present study describes the isolation and characterization of a bacteriophage effective against the important clinical pathogen Escherichia coli, which shows increasing accumulation of antibiotic resistance. Phage fEg-Eco19, which is specific for a clinical E. coli strain, was isolated from an Egyptian sewage sample. Phage fEg-Eco19 formed clear, sharp-edged, round plaques. Electron microscopy showed that the isolated phage is tailed and therefore belongs to the order Caudovirales, and morphologically, it resembles siphoviruses. The diameter of the icosahedral head of fEg-Eco19 is 68 ± 2 nm, and the non-contractile tail length and diameter are 118 ± 0.2 and 13 ± 0.6 nm, respectively. The host range of the phage was found to be narrow, as it infected only two out of 137 clinical E. coli strains tested. The phage genome is 45,805 bp in length with a GC content of 50.3% and contains 76 predicted genes. Comparison of predicted and experimental restriction digestion patterns allowed rough mapping of the physical ends of the phage genome, which was confirmed using the PhageTerm tool. Annotation of the predicted genes revealed gene products belonging to several functional groups, including regulatory proteins, DNA packaging and phage structural proteins, host lysis proteins, and proteins involved in DNA/RNA metabolism and replication.

1 December 2014 in Scientific Journal for Damietta Faculty of Science
Verified
Journal Article
Closed access
PDF file
ZBZakaria A. Baka
Zakaria A. Baka
MDMohamed I. Abou Dobara
Mohamed I. Abou Dobara
AEAhmed K. El-Sayed
Ahmed K. El-Sayed
SBShimaa Badawy
Shimaa Badawy
Nosocomial infections are frequent complications of hospitalization, caused by opportunistic pathogens that gain access to hosts undergoing invasive procedures. This study was carried out to investigate the presence of antibiotic resistance bacteria from hospital environment of Damietta, Egypt. Two hundred and six clinical bacterial isolates were collected from different samples (sink, floor, bed, bed cover, toilet floor, bed pan, ward wall and hospital staff apparel (protective gowns, hand groves and face-shield) within reception hall, maternity ward, convalescing wards, surgical theaters, intensive care, dental unit, pharmacy and laboratory) from (Kafr Saad General Hospital and El-Azhar University Teaching Hospital). Four bacterial species were identified as Bacillus subtilis, Bacillus cereus, Klebsiella pneumoniae and Enterobacter aerogenes using standard morphological, biochemical tests and sequencing of 16S rRNA gene. Eleven antibiotics (Trimethoprim/sulphamethoxazole (25 μg); Rifampicin (5 μg); Piperacillin/tazobactam (110 μg); Ofloxacin (5 μg); Nitrofurantoin (300 μg); Imipenem (10 μg); Gentamicin (120 μg); Ceftriaxone (30 μg); Cefotaxime (30 μg); Amikacin (30 μg) and Amoxicillin/clavulanic acid (30 μg) were tested against the bacterial isolates using disc diffusion method to determine the multi-drug resistance bacteria. Imipanem was found to be as the most effective drug against Klebsiella pneumoniae while ofloxacin, amikacin, piperacillin/tezobactam, gentamicin and rifampcin had low effect against Klebsiella pneumoniae and no effect of amoxicillin/clavulanic acid, cefotaxime, ceftriaxone, nitrufurantion and trimethoprim/sulehamethoxazole was recorded against Bacillus subtilis.